{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349107","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2026-08-13T20:00:18+00:00","discovered_at":"2026-08-13T20:01:17.051168+00:00","generated_at":"2026-08-13T20:01:21.027748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kodiak Q2 net loss $65.6M; DAYBREAK topline due Sept 2026, cash into 2027","bullets":["Q2 2026 net loss $65.6M ($1.05/sh) vs $54.3M ($1.03/sh) in Q2 2025; SBC $11.6M.","Cash and equivalents $125.9M at June 30, 2026; expected to fund operations into 2027.","R&D expense $56.1M (up from $42.8M) on PEAK/PINNACLE and manufacturing; G&A $10.8M.","Phase 3 DAYBREAK topline (Zenkuda/KSI-501, wet AMD) expected Sept 2026; PEAK Pivotal Analysis 1 (KSI-101, MESI) Dec 2026.","Enrollment completed for first 300-patient PEAK cohort; ALTO Phase 3 (KSI-501 vs aflibercept, DME) patient enrollment initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349107","json":"https://secwatch.observer/filing/0001193125-26-349107.json","markdown":"https://secwatch.observer/filing/0001193125-26-349107.md","text":"https://secwatch.observer/filing/0001193125-26-349107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/0001193125-26-349107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:01:21.027748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}